Pharma BD Deal Intelligence

Merck & Co., Inc. / Isomorphic Labs

2026 · Co-Development · Complete

Merck & Co., Inc. (known as MSD outside the United States and Canada) and Isomorphic Labs entered a strategic research collaboration to discover therapeutic small molecule candidates against an undisclosed oncology target of strategic importance. Isomorphic Labs will perform in silico predictions and deliver molecular designs using its proprietary drug design engine (IsoDDE), incorporating select proprietary Merck data sets supplied for the collaboration; Merck is responsible for preclinical and clinical development, manufacturing and commercialization of any resulting products. Isomorphic receives an undisclosed upfront payment plus eligibility for research, development, regulatory and commercial milestones and tiered royalties, and holds an option to co-fund development in return for elevated royalties. No financial terms were disclosed. The agreement follows Isomorphic's $5 billion fundraise and adds Merck to a partner roster that already included Novartis and Eli Lilly.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →